Literature DB >> 32232924

Beta human papillomaviruses infection and skin carcinogenesis.

Luigia Bandolin1, Daniele Borsetto2, Jonathan Fussey3, Maria Cristina Da Mosto1, Piero Nicolai1, Anna Menegaldo1, Luca Calabrese4, Massimo Tommasino5, Paolo Boscolo-Rizzo1.   

Abstract

During the last decade, the worldwide incidence of keratinocyte carcinomas (KC) has increased significantly. They are now the most common malignancy, representing approximately 30% of all cancers. The role of ultraviolet (UV) radiation as a major environmental risk factor for skin cancers is well recognized. The aim of this review is to analyse the current understanding of the nature of beta-human papillomavirus (HPV) and its association with KC and explore the implications for the management and prevention of these cancers. A comprehensive review of the literature on beta-HPV and its association with KC was undertaken, the results reported in the form of a narrative review. A subgroup of HPV that infects the mucosal epithelia of the genital tract has been firmly associated with carcinogenesis. In addition, some HPV types with cutaneous tropism have been proposed to cooperate with UV in the development of KC. The first evidence for this association was reported in 1922 in patients with epidermodysplasia verruciformis (EV). Since then, epidemiological studies have highlighted the higher risk of skin cancer in patients with EV and certain cutaneous HPV types, and in vitro studies have elucidated molecular mechanisms and transforming properties of beta-HPV. Furthermore, in vivo research conducted on transgenic mice models has shown the possible role of beta-HPV in cutaneous carcinogenesis as a co-factor with UV radiation and immunosuppression. There is good evidence supporting the role of beta-HPV in the oncogenesis of KC. The high prevalence of beta-HPV in human skin and the worldwide burden of KC makes the search for an effective vaccine relevant and worthwhile.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Beta HPV types; E6 and E7 oncoproteins; UV irradiation; skin cancer; vaccine

Year:  2020        PMID: 32232924     DOI: 10.1002/rmv.2104

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  6 in total

Review 1.  Effects of β-HPV on DNA damage response pathways to drive carcinogenesis: a review.

Authors:  Danyal Tahseen; Peter L Rady; Stephen K Tyring
Journal:  Virus Genes       Date:  2021-01-03       Impact factor: 2.332

2.  Beta Human Papillomavirus 8 E6 Induces Micronucleus Formation and Promotes Chromothripsis.

Authors:  Dalton Dacus; Steven Stancic; Sarah R Pollina; Elizabeth Rifrogiate; Rachel Palinski; Nicholas A Wallace
Journal:  J Virol       Date:  2022-09-21       Impact factor: 6.549

Review 3.  Beyond MicroRNAs: Emerging Role of Other Non-Coding RNAs in HPV-Driven Cancers.

Authors:  Mariateresa Casarotto; Giuseppe Fanetti; Roberto Guerrieri; Elisa Palazzari; Valentina Lupato; Agostino Steffan; Jerry Polesel; Paolo Boscolo-Rizzo; Elisabetta Fratta
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

4.  Mus musculus papillomavirus 1 is a key driver of skin cancer development upon immunosuppression.

Authors:  Sonja Dorfer; Katharina Strasser; Georg Schröckenfuchs; Michael Bonelli; Wolfgang Bauer; Harald Kittler; Christophe Cataisson; Michael B Fischer; Beate M Lichtenberger; Alessandra Handisurya
Journal:  Am J Transplant       Date:  2020-11-03       Impact factor: 8.086

5.  HPV8 Reverses the Transcriptional Output in Lrig1 Positive Cells to Drive Skin Tumorigenesis.

Authors:  Adnan Shahzad Syed; Gian Paolo Marcuzzi; Daliborka Miller-Lazic; Jochen Hess; Martin Hufbauer; Baki Akgül
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

6.  Restriction of viral gene expression and replication prevents immortalization of human keratinocytes by a beta-human papillomavirus.

Authors:  Tina M Rehm; Elke Straub; Thomas Iftner; Frank Stubenrauch
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-07       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.